SPOTLIGHT: Abbott hit with antitrust suit

Pharmacies and a wholesaler slapped Abbott Laboratories with an antitrust lawsuit over the price of its AIDS drug Norvir, which jumped 400 percent in 2003. Report

Suggested Articles

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.